In Vitro Activity of Tedizolid Against Gram-Positive Bacteria in Patients With Skin and Skin Structure Infections and Hospital-Acquired Pneumonia: A Korean Multicenter Study

Abstract

We compared the activities of tedizolid to those of linezolid and other commonly used antimicrobial agents against gram-positive cocci recovered from patients with skin and skin structure infections (SSSIs) and hospital-acquired pneumonia (HAP) in Korean hospitals. Gram-positive isolates were collected from 356 patients with SSSIs and 144 patients with HAP at eight hospitals in Korea from 2011 to 2014. SSSIs included impetigo, cellulitis, erysipelas, furuncles, abscesses, and infected burns. Antimicrobial susceptibility was tested by using the CLSI agar dilution method. All of the gram-positive isolates were inhibited by ≤1 µg/mL tedizolid. The minimum inhibitory concentration [MIC]90 of tedizolid was 0.5 µg/mL for methicillin-resistant Staphylococcus aureus, which was 4-fold lower than that of linezolid. Tedizolid may become a useful option for the treatment of SSSIs and HAP caused by gram-positive bacteria.

Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014

“…Numerous in vitro surveys have demonstrated that tedizolid is 4-to 8-fold more potent than linezolid against species of staphylococci, enterococci, and streptococci, including those with multidrug-resistant (MDR) phenotypes, such as MRSA, VRE, and linezolid-resistant S. aureus and enterococci (3)(4)(5). Structural modifications in the molecule result in enhanced binding to the 23S rRNA target and provide enhanced activity of tedizolid compared to that of linezolid; furthermore, tedizolid potency is not affected by strains harboring the transmissible cfr resistance gene (1,2,6).…”

Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections

“…strains, while linezolid’s MIC range was 0.5–2 mg/L 54. Tedizolid MIC 90 value was 0.5 mg/L against 873 enterococci included in other study while linezolid’s MIC 90 was 2 mg/L 56…”

“…Tedizolid shows excellent activity against anaerobic Gram-positive microorganisms 54. Tedizolid’s MIC range against these microorganisms was four to eight times lower than that observed with linezolid.…”

“…Finally, tedizolid’s MIC range was 0.25–0.5 mg/L for S. agalactiae strains and 0.125–0.5 mg/L for S. pyogenes strains, while linezolid’s MIC range was 2–4 mg/L for S. agalactiae strains and 1–2 mg/L for S. pyogenes strains 54. Tedizolid MIC 90 values for S. agalactiae , S. pyogenes , and other β-hemolytic streptococci were each 0.25 mg/L, whereas linezolid’s MIC 90 was 1 mg/L 56,58…”

“…54–59 In one study, tedizolid’s MIC range was 0.125–0.5 mg/L against MRSA strains from SSSIs, while linezolid’s MIC range was 0.25–4 mg/L 54. The most effective drugs against MRSA were tedizolid (MIC 90 of 0.5 mg/L), linezolid (MIC 90 of 2 mg/L), and vancomycin (MIC 90 of 2 mg/L).…”